Skip to main content
. 2021 Jun 18;12:3742. doi: 10.1038/s41467-021-23957-5

Fig. 2. The mode of expression of oncogenic KRAS determines the molecular subtype of mammary cancers.

Fig. 2

Microarray-based gene expression and cluster analysis to compare the molecular profiles of mammary tumors that originated in MMTV-tTA TetO-KrasG12D (yellow arrows, N = 4 biological replicates) and WAP-Cre EF1-tTA TetO-KrasG12D (red arrows, N = 4 biological replicates) transgenic females with reference sets from diverse genetically engineered, as well as chemical-induced and radiation-induced mammary cancer models. Note that the TetO-KrasG12D transgene is under the control of the tetracycline-responsive transactivator (tTA) in both models. In contrast to the epithelial-specific expression of the tTA under the MMTV-LTR, the WAP-Cre-mediated activation of oncogenic KRAS in the luminal epithelium is under the control of the ubiquitously active EF1-tTA, which is untethered from a differentiation state and allows neoplastic cells to assume diverse developmental fates.